Prestige Wealth Management Group LLC Has $5.25 Million Position in Johnson & Johnson (NYSE:JNJ)

Prestige Wealth Management Group LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,134 shares of the company’s stock after buying an additional 1,171 shares during the period. Johnson & Johnson comprises about 1.5% of Prestige Wealth Management Group LLC’s investment portfolio, making the stock its 18th biggest holding. Prestige Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $5,250,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares during the last quarter. FMR LLC lifted its stake in shares of Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in Johnson & Johnson by 0.3% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock worth $1,333,545,000 after acquiring an additional 24,505 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the transaction, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The disclosure for this sale can be found here. Insiders have sold a total of 277,886 shares of company stock worth $48,550,549 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $168.74 on Friday. The firm has a market cap of $441.17 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The company’s 50-day moving average price is $176.14 and its two-hundred day moving average price is $171.25.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.68%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Morgan Stanley cut their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Raymond James cut their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Credit Suisse Group started coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price for the company. Bank of America dropped their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Finally, SVB Leerink dropped their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.